This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here's Why Organon (OGN) Gained But Lagged the Market Today
by Zacks Equity Research
In the closing of the recent trading day, Organon (OGN) stood at $18.10, denoting a +0.56% change from the preceding trading day.
Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Organon (OGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Organon (OGN) closed at $18.10 in the latest trading session, marking a -0.11% move from the prior day.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is WisdomTree U.S. SmallCap Dividend ETF (DES) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DES
Organon (OGN) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Organon (OGN) concluded the recent trading session at $18.58, signifying a -1.33% move from its prior day's close.
Why Organon (OGN) Outpaced the Stock Market Today
by Zacks Equity Research
Organon (OGN) reachead $19.17 at the closing of the latest trading day, reflecting a +0.74% change compared to its last close.
Are Options Traders Betting on a Big Move in Organon (OGN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Organon (OGN) stock based on the movements in the options market lately.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
by Zacks Equity Research
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon (OGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Organon (OGN) concluded the recent trading session at $20.18, signifying a +1.05% move from its prior day's close.
Organon (OGN) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Organon (OGN) concluded the recent trading session at $20.47, signifying a +0.89% move from its prior day's close.
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Is Trending Stock Organon & Co. (OGN) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DES
Is Most-Watched Stock Organon & Co. (OGN) Worth Betting on Now?
by Zacks Equity Research
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon (OGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Organon (OGN) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 5.66% and 1.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Product Demand Likely to Aid Organon's (OGN) Q2 Earnings
by Zacks Equity Research
Continued solid uptake of Organon's (OGN) products is expected to have driven second-quarter revenues.
Do Options Traders Know Something About Organon (OGN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Organon (OGN) stock based on the movements in the options market lately.
Seeking Clues to Organon (OGN) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Organon (OGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Organon (OGN) closed at $21.86, marking a -1.84% move from the previous day.
Is WisdomTree U.S. SmallCap Dividend ETF (DES) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DES
Earnings Preview: Organon (OGN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH